Variable | Poor performance on SAATSA Access Scale n (%) | Unadjusted association | Adjusted association | ||
---|---|---|---|---|---|
ORa | 95% CIb | aORc | 95% CI | ||
Gender | |||||
Male | 318 (39.1) | Reference | Reference | ||
Female | 99 (35.0) | 0.84 | 0.59–1.19 | 0.89 | 0.69–1.27 |
Race | |||||
Black African | 44 (57.1) | Reference | Reference | ||
Colouredd | 308 (34.9) | 0.22 | 0.12–0.40*** | 0.23 | 0.11–0.51*** |
White | 60 (41.6) | 0.34 | 0.21–0.57*** | 0.28 | 0.11–0.71** |
Indian | 5 (47.6) | 1.24 | 0.10–14.96 | 1.24 | 0.11–12.70 |
Age (M, SE) in years | 33.7 (0.58) | 1.01 | 0.99–1.03 | 0.98 | 0.96–1.00 |
Education | |||||
Not completed school | 174 (33.0) | 0.66 | 0.41–1.07 | – | |
Employment | |||||
Employed | 127 (44.2) | 1.42 | 0.99–2.05 | 1.13 | 0.71–1.75 |
Comorbid physical noncommunicable disease | 56 (50.0) | 1.84 | 1.26–2.70*** | 1.84 | 0.99–3.52 |
Comorbid mental health | 51 (51.0) | 1.92 | 1.01–3.88* | 1.91 | 1.16–3.14** |
Primary substance | |||||
Stimulants | 145 (35.1) | 0.58 | 0.40–0.84** | 0.84 | 0.46–1.58 |
Heroin | 96 (36.5) | 0.51 | 0.35–0.74** | 1.03 | 0.45–2.36 |
Cannabis | 23 (32.1) | 0.61 | 0.38–0.98* | 0.81 | 0.40–1.62 |
Methaqualone | 34 (40.0) | 0.71 | 0.35–1.44 | 1.04 | 0.43–2.23 |
Alcohol | 73 (48.3) | Reference | Reference | ||
Polysubstance use | 227 (35.0) | 1.32 | 1.01–1.75* | 1.26 | 0.89–1.79 |
Chronicity: years of use (M, SE) | 15.12 (0.79) | 1.02 | 1.00–1.03* | 1.02 | 1.02–1.05** |
Frequency of use | |||||
Daily | 276 (35.7) | 2.41 | 0.52–1.10 | – | |
2–6 times per week | 84 (42.2) | 3.17 | 0.69–14.57 | ||
Weekly | 10 (37.0) | 2.54 | 0.53–12.28 | ||
Monthly | 3 (18.8) | Reference | |||
Prior SUD treatment No | 190 (37.7) | Reference | |||
Yes | 227 (38.2) | 1.02 | 0.79–1.32 | – | |
Treatment intensity | |||||
Outpatient | 215 (31.6) | Reference | Reference | ||
Residential | 202 (48.4) | 2.03 | 1.40–2.96** | 1.69 | 1.08–2.64** |
State-funded treatment | |||||
Yes | 286 (34.3) | 0.53 | 0.29–0.96* | 0.90 | 0.53–1.54 |
No | 131 (49.8) | Reference | Reference |